Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc.
Your view on CERE
Overview
What the company does, where it operates, and who runs it.
About Cerevel Therapeutics Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ronald C. Renaud Jr.,
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ronald C. Renaud Jr.,
- Headquarters
- US
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.
It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.
The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder.
It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Cerevel Therapeutics Holdings, Inc. from FRC's valuation model, read against the market price. CERE last traded at $44.96; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cerevel Therapeutics Holdings, Inc.. Starting points for Cerevel Therapeutics Holdings, Inc.: EPS -$2.67, beta 1.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Cerevel Therapeutics Holdings, Inc.. Cerevel Therapeutics Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cerevel Therapeutics Holdings, Inc.. Trailing twelve-month EPS for Cerevel Therapeutics Holdings, Inc. stands at -$2.67. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$33.50
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy6
- Hold10
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2024 | Next QtrSep 2024 | Current YearFY Dec 2024 | Next YearFY Dec 2025 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | -$0.73 | -$2.91 | -$3.15 |
| Low estimate | $0.00 | -$0.73 | -$3.59 | -$3.54 |
| High estimate | $0.00 | -$0.73 | -$1.98 | -$2.81 |
| No. of analysts | 1 | 1 | 4 | 3 |
| Year-ago EPS | — | — | -$2.67 | — |
| Growth | — | — | -9.1% | — |
Revenue Estimate
| Revenue | Current QtrJun 2024 | Next QtrSep 2024 | Current YearFY Dec 2024 | Next YearFY Dec 2025 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $0.00 | $13.52M |
| Low estimate | $0.00 | $0.00 | $0.00 | $13.52M |
| High estimate | $0.00 | $0.00 | $0.00 | $13.52M |
| No. of analysts | 0 | 0 | 0 | 3 |
| Year-ago revenue | — | — | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cerevel Therapeutics Holdings, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ROIVRoivant Sciences Ltd.Biotechnology$28.0B
More Biotechnology companies
- VXRTVaxart, Inc.OTC$129M
- VYGRVoyager Therapeutics, Inc.NASDAQ$101M
- WHWKWhitehawk Therapeutics IncNASDAQ$178M
- WINTWindtree Therapeutics, Inc.NASDAQ$2M
- WSNAFWesana Health Holdings Inc.OTC$341,000
- WVEWave Life Sciences Ltd.NASDAQ$566M
- WXIBFWuXi Biologics (Cayman) Inc.OTC$21.3B
- WXXWYWuXi Biologics (Cayman) Inc.OTC$21.7B
- XAGELongevity Health Holdings Inc.OTC$415,447
- XBIOXenetic Biosciences, Inc.NASDAQ$3M
- XBITXBiotech Inc.NASDAQ$56M
- XCURExicure, Inc.NASDAQ$7M
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Cerevel Therapeutics Holdings, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Cerevel Therapeutics Holdings, Inc.. Coverage tracks Cerevel Therapeutics Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cerevel Therapeutics Holdings, Inc.